Our Practice Advisory for Physician Workflow

Overseen By Katelyn Clinical Research Coordinator

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: University of California, Los Angeles

Disqualifiers: No recent A1c or TSH

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

384 Participants Needed

Trial Summary

What is the purpose of this trial?

Our Practice Advisory (OPA) are essential tools in clinical decision-making. The alerts are designed to guide providers towards evidence-based practices and improve patient outcomes. The focus of this initiative is on Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) testing, with the goal of addressing unnecessary repeat testing within a 30-day timeframe, which rarely yields significant new insights. Although randomization occurs at the patient level, the primary outcome of this study focuses on provider behavior and decision-making. By focusing on this specific intervention, the study aims to optimize resource use, align test ordering with evidence-based guidelines, and support improved patient outcomes. The results of this evaluation will help refine OPAs and guide broader strategies for implementing clinical decision support tools across healthcare systems.

Eligibility Criteria

This trial is for healthcare providers who order Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. It aims to improve their decision-making by reducing unnecessary repeat testing within a short period.

Inclusion Criteria

I am 18 years old or older.

Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) ordered, AND this lab was ordered and resulted within the prior 30 days

Inpatient or observation stays within UCLA Health System hospitals

Exclusion Criteria

Have an A1c or TSH ordered and do not have a result for one of these labs in the prior 30 days

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Providers receive or do not receive the Our Practice Advisory (OPA) when ordering A1c and TSH tests within 30 days of prior results

6 months

Follow-up

Participants are monitored for changes in test ordering behavior and outcomes

4 weeks

Treatment Details

Interventions

• Our Practice Advisory (OPA)

Trial Overview The study evaluates the effectiveness of Our Practice Advisory (OPA), which are alerts that guide providers towards evidence-based practices, particularly in ordering A1c and TSH tests.

Participant Groups

Group I: OPA Intervention Group Experimental Treatment 1 Intervention

Providers in this group will receive a Our Practice Advisory (OPA) through the electronic health record (EHR) system when ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. The OPA will prompt providers to reconsider the test if it was ordered within the previous 30 days, aligning with evidence-based guidelines to reduce unnecessary testing.

Group II: Control Group Active Control 1 Intervention

Providers in this group will not receive a Our Practice Advisory (OPA) through the Electronic Health Record (EHR) system when ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. This group represents the current standard of care, with no additional prompts or alerts implemented.

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials

1,594

Recruited

10,430,000+